RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that
is pioneering the use of robotics to improve minimally invasive surgery,
today provided a year-end corporate update.
"2017 was a transformational year for TransEnterix that included the
commencement of U.S. Senhance commercialization and progression towards
the global commercialization of SurgiBot," said Todd M. Pope, President
and CEO at TransEnterix. "We are very excited about the opportunity that
lies ahead in 2018 as we look to build upon our momentum and drive the
global adoption of the Senhance."
Senhance System Revenue
During the quarter ending December 31, 2017, the Company sold two
Senhance Systems for total revenue of approximately $3.3 million. Total
2017 revenue is approximately $7.0 million, a 360% increase over 2016,
representing a total of five Senhance Systems: Europe (two), Asia (two,
including one sale for which the revenue was not recognized in 2017) and
the United States (one).
The company currently has received one European Senhance System order
that it expects to deliver and recognize revenue for in the quarter
ending March 31, 2018.
During 2017, the company completed the following product portfolio
Obtained Senhance System FDA 510(k) clearance for use in colorectal
and gynecologic laparoscopic surgery
Obtained CE mark and began commercializing the world's first robotic
micro-laparoscopic (3 millimeter) instruments
Expanded list of compatible visualization and fluorescence systems to
include systems from Stryker, Novadaq (Stryker), Conmed and Richard
Filed approximately 40 new US patent applications. The Company's
patent portfolio now includes approximately 93 issued patents, 25 of
which are US Patents, as well as approximately 92 pending
applications, 54 of which are US applications.
The Company expects to complete the following product portfolio
initiatives in 2018:
Expand the Senhance System US FDA clinical indications to include
hernia and gallbladder, doubling the total addressable market
Launch new ultrasonic energy device
Launch new five-millimeter articulating instrument platform
SurgiBot Global System Agreement
On December 18, 2017, the Company announced that it had entered into an
agreement with Great Belief International Limited (GBIL) to advance the
SurgiBot System towards global commercialization.
The agreement provides the Company with proceeds of at least $29
million, of which $7.5 million was received in December of 2017. An
additional $7.5 million is expected to be received by March 31, 2018,
including a $3.0 million equity investment at $2.33 per share. The
remaining $14 million, representing minimum royalties, will be paid
beginning at the earlier of receipt of Chinese regulatory approval or
This agreement transfers ownership of the SurgiBot System assets, while
the Company retains the option to distribute or co-distribute the
SurgiBot system outside of China. Upon completion of the transfer of all
SurgiBot system assets, GBIL will have the SurgiBot system manufactured
in China and obtain Chinese regulatory clearance from the China Food and
Drug Administration ("CFDA"), while entering into a nationwide
distribution agreement with China National Scientific and Instruments
and Materials Company (CSIMC) for the Chinese market.
As of December 31, 2017, the Company's cash and restricted cash balance
was approximately $97 million. The Company believes that this capital is
sufficient to fund operations through the year 2019.
As of December 31, 2017, there were approximately 199 million shares of
common stock outstanding.
About TransEnterix, Inc.
TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options in today's value-based healthcare environment. The
company is focused on the commercialization of the Senhance™
Surgical Robotic System, a multi-port robotic system that brings the
advantages of robotic surgery to patients while enabling surgeons with
innovative technology such as haptic feedback and eye sensing camera
control. The Senhance Surgical Robotic System is available for sale in
the US, the EU and select other countries. For more information, visit
the TransEnterix website at www.transenterix.com.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which are intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and
uncertainties that are often difficult to predict, are beyond our
control and which may cause results to differ materially from
expectations, including whether we will be able to build upon our
momentum and drive the global adoption of the Senhance in 2018; whether
we will deliver and recognize revenue from the sale of a European
Senhance System in the 2018 first quarter; whether we will expand the
Senhance System US FDA clinical indications to include hernia and
gallbladder; whether we will launch a new ultrasonic energy device,
whether we will launch a new five-millimeter instrument platform;
whether TransEnterix will receive at least $29 million (including
minimum royalties) from GBIL; whether GBIL will be able to obtain the
necessary clearances to sell the SurgiBot System in China; whether
TransEnterix will be able to successfully distribute or co-distribute
the SurgiBot System outside of China, and realize revenues beyond the
initial consideration and minimum royalties; and whether our cash
through December 31, 2017 will be sufficient capital to fund operations
through the year 2019. We cannot assure you that our expectations will
be realized. For a discussion of the risks and uncertainties associated
with TransEnterix's business, please review our filings with the
Securities and Exchange Commission (SEC), including our Annual Report on
Form 10-K filed on March 6, 2017 and our other filings we make with the
SEC. You are cautioned not to place undue reliance on these forward
looking statements, which are based on our expectations as of the date
of this press release and speak only as of the origination date of this
press release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new information,
future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108005939/en/
For TransEnterix, Inc.
Mark Klausner, +1
Rice, + 1 951-751-1858
Source: TransEnterix, Inc.
News Provided by Acquire Media